Abstract: A plunger for use with a syringe includes a plunger body defining a central longitudinal axis and having a proximal end, a distal end, and a circumferential sidewall connecting the proximal end and the distal end. The plunger further includes at least one retaining member associated with and extending proximally from the plunger body. The at least one retaining member has a first end connected to the plunger body, a second end proximal to the first end and radially and resiliently deflectable relative to the first end, and at least one catch on the second end. A fluid injector system includes a piston having a plunger engagement mechanism configured for interacting with the at least one retaining element of the plunger to releasably engage the plunger for reciprocally driving the plunger within a barrel of the syringe.

Abstract: A syringe includes a barrel having a proximal end, a distal end, and a sidewall extending substantially circumferentially between the proximal end and the distal end along a longitudinal axis. The barrel is formed from an injection molding process including aligning a mold die defining an internal shape of the barrel in a molding cavity defining an external shape of the barrel, the molding cavity defined by first and second mold sections. Each mold section includes at least one gate adapted to control the flow of a molding material into the molding cavity. The gates of each mold section are opened to permit the first and second melt streams of molding material to fill the molding cavity surrounding the mold die, where the molding material takes the shape of the molding cavity.

Abstract: A fluid injector system has a controller for operably controlling the injection of contrast and/or saline into a patient. The controller allows a user to program a diagnostic injection procedure having one or more phases according to which the contrast and/or saline will be injected into the patient so as to effect enhancement of a region thereof during an imaging procedure. It further allows the user to program a test injection procedure to be performed prior to the diagnostic injection procedure. The test injection procedure is implementable as: (a) a variable single phase test injection in which the rate at which the saline is to be delivered is selectable prior to and may be varied during performance thereof; and/or (b) a multi-phase test injection in which the rate at which the saline is to be delivered is selectable for each phase of the multi-phase test injection prior to performance thereof.

Abstract: The present invention covers aminoquinolone compounds of general formula (I), in which R1, R2, R3, R4, R5, R6, R7, R8 and n are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment and/or prophylaxis of diseases, in particular of diacylglycerol kinase alpha regulated disorders, as a sole agent or in combination with other active ingredients.

Abstract: Described are systems and methods for assessing a likelihood of chronic thromboembolic pulmonary hypertension (CTEPH) within a subject patient based upon an analysis of characteristics indicative of chronic thromboembolic pulmonary hypertension within an imaging study of the subject patient. The systems and methods can identify characteristics of one or more anatomical structures within a cardiac region of the subject patient indicative of CTEPH, characteristics of a pulmonary vasculature of the subject patient indicative of CTEPH, and characteristics of a chronic abnormality in a lung of the subject patient indicative of CTEPH. The systems and methods can assess these characteristics to compute the likelihood of CTEPH within the subject patient.

Abstract: A method is provided for authenticating, and establishing and tracking eligibility of a patient to purchase an over-the-counter (OTC) drug from a retailer, the patient using a client device or terminal and the retailer having a server. The server is configured to redirect the client device or terminal to a backend platform to authenticate the patient, access a storage to search for any information that indicates the patient is ineligible to purchase the OTC drug; and without any information that indicates the patient is ineligible, administer a questionnaire to the patient to assess the eligibility for the OTC drug. And the backend platform redirects the client device or terminal back to the server to complete the online sale of the OTC drug to the patient when the patient is eligible, or cancel the online sale of the OTC drug to the patient when the patient is ineligible.

Abstract: The present invention relates to Map4K1 inhibitors of formula (I) (I), wherein A, E, G, Q, R1, R2 and R4 have the same meaning as defined in the description, to pharmaceutical compositions and combinations comprising the compounds according to the invention, and to the prophylactic and therapeutic use of the inventive compounds, respectively to the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular for neoplastic disorders, respectively cancer or conditions with dysregulated immune responses or other disorders associated with aberrant MAP4K1 signaling, as a sole agent or in combination with other active ingredients.

Abstract: The present invention relates to an inserter for an intrauterine system comprising a handle (3), and an insertion tube (6) having a first end and a second end, and being arranged in connection with the handle. The inserter is characterized in that the first end of the insertion tube (6) comprises at least one frame slot for receiving a frame of the intrauterine system. The invention also relates to a kit comprising an inserter according to the present invention and an intrauterine system, wherein the intrauterine system (1) comprises a therapeutic component (1b) and a continuous, closed frame (1a), the therapeutic component (1b) being connected to the frame (1a) at least one point, and therapeutic component (1b) of the intrauterine system (1) is at least mainly arranged inside the first end of the insertion tube (6) and the frame (1a) of the intrauterine system (1) is at least mainly arranged outside the first end of the insertion tube (6).

Abstract: An inserter for an intrauterine system can include a handle having an opening, a slider arranged in the opening, a plunger attached to the handle, an insertion tube attached to the slider and arranged around the plunger, and a lock adapted to reversibly lock at least one removal string of the intrauterine system. The lock can include a main part with an opening, the main part being rotatably mounted on a shaft or axle, an extension of the main part, and a counterpart. The removal string passes through the opening of the main part and is immobilized between the main part and the counterpart when the lock is in a locking position. The slider is configured to press against the extension of the main part and turn the main part around the shaft or axle to release the removal string as the slider is moved backwards.

Abstract: The present application relates to substituted indazoles, to the use thereof alone or in combinations for treatment and/or prophylaxis of autoimmune disorders, and to the use thereof for production of medicaments for treatment and/or prophylaxis of autoimmune disorders, especially for treatment and/or prophylaxis of arthritides (especially psoriatic arthritis, rheumatoid arthritis, Bekhterev's disease, reactive arthritis, systematic juvenile idiopathic arthritis), systematic lupus erythematosus, multiple sclerosis, psoriasis, atopic dermatitis, allergic eczema and chronic-inflammatory bowel disorders (especially Crohn's disease and ulcerative colitis).

Abstract: The present disclosure provides for suspension-based pharmaceutical formulations for cold and flu medications, specifically suspension formulations and soft gel capsule dosage forms having reduced size. The present disclosure also provides methods of preparing the suspensions and soft gel capsule dosage forms.

Abstract: A method and system determine, with a computer system including one or more processors, a plurality of parameters associated with a volume in an object over time in a series of sequence blocks. In a sequence block in the series of sequence blocks, the plurality of parameters are determined as occurring simultaneously in the volume in the object. At least one parameter of the plurality of parameters varies from the sequence block to another sequence block in the series of sequence blocks, and the plurality of parameters include a contrast related parameter associated with a concentration of a contrast agent in the volume in the object over time in the series of sequence blocks. The computer system generates a signal evolution based on the plurality of parameters of the volume in the object over time in the series of sequence blocks, the signal evolution defining the contrast related parameter over time in the series of sequence blocks.

Abstract: The present invention covers compounds of general formula (I): [(C)n-L]-(V)m (I) where C is a chelator and n>1, L is a multi-functional linker moiety comprising multiple functional groups for the covalent attachment of chelator such as a polyamine or polyacid-containing backbone or amino acid containing polymer comprising side-chains with amino, thiol or carboxylic acid moieties such as lysine, cysteine or glutamic acid and V is a tissue targeting moiety where m=1-5 which preferentially coupled through a coupling moiety to either the multifunctional linker moiety L or directly to the chelator moiety C, and stereoisomers, tautomers, N-oxides, hydrates, solvates, and salts thereof, and mixtures of same.

Abstract: A method, system, and computer program product for peer exchange of data between injection systems. A first injection system may store a plurality of injection control data sets, determine a first subset of the plurality of injection control data sets according to which the first injection system is configured to control delivery of fluid to a patient, provide the first subset of the plurality of injection control data sets for selection of an injection control data set for use in delivering fluid to the patient with the first injection system, and transmit the plurality of injection control data sets to at least one second injection system.

Abstract: The present invention includes compounds of formula (I) and methods for its preparation and treatment of disorders with activated peroxisome preoliferator-activated receptor gamma (PPARG), particularly cancer.

Abstract: The present invention relates to the technical field of producing artificial contrast-enhanced radiological images by way of machine learning methods.

Abstract: The present invention covers 2-[(3R)-3-methylmorpholin-4-yl]-4-(1-methyl-1H-pyrazol-5-yl)-8-(1H-pyrazol-5-yl)-1,7-naphthyridine (in the following called “Compound A”), an inhibitor of ATR kinase, for use in a method of treating a hyper-proliferative disease in a subject.

Abstract: An engagement mechanism associated with a reciprocally movable piston of a fluid injector is configured for releasably engaging an engagement portion at a proximal end of a rolling diaphragm syringe having a flexible sidewall configured for rolling upon itself when acted upon by the piston. The engagement mechanism has a plurality of engagement elements reversibly and radially movable relative to the engagement portion of the syringe between a first position, where the plurality of engagement elements are disengaged from the engagement portion of the syringe, and a second position, where the plurality of engagement elements are engaged with the engagement portion of the syringe. The engagement mechanism further has a drive mechanism for moving the plurality of engagement elements between the first position and the second position.